Development of an Intracellular Tau-Specific Antibody Therapeutic for the Treatment of Alzheimer's Disease

Grant number: 2000968 | Funding period: 2021 - 2023

Completed

Abstract

The protein, tau, is a promising therapeutic target for the treatment of Alzheimer's disease and related dementia's. Targeting tau is a challenge, however, as it is mostly localised within brain cells and a therapeutic must therefore be able to cross multiple barriers to engage and neutralise tau. This project overcomes this hurdle by using virus' to deliver a tau-specific antibody gene across the multiple barriers where it can be produced by brain cells and target intracellular tau.

Related publications (3)

Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau

Patricia Wongsodirdjo, Alayna C Caruso, Alicia K Yong, Madeleine A Lester, Laura J Vella, Ya Hui Hung, Rebecca M Nisbet

2024-01-01

Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer’s disease. In ..

Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy

Rinie Bajracharya, Esteban Cruz, Jurgen Gotz, Rebecca M Nisbet

2022-09-01

Tau-specific immunotherapy is an attractive strategy for the treatment of Alzheimer's disease and other tauopathies. However, effe..

Current and emerging strategies for enhancing antibody delivery to the brain

R Bajracharya, AC Caruso, LJ Vella, RM Nisbet

2021-12-01

For the treatment of neurological diseases, achieving sufficient exposure to the brain parenchyma is a critical determinant of dru..

University of Melbourne Researchers

Rebecca M. Nisbet